Cargando…

Immunogenicity and Safety of Adjuvanted Recombinant Zoster Vaccine in Rheumatoid Arthritis Patients on Anti-Cellular Biologic Agents or JAK Inhibitors: A Prospective Observational Study

Rheumatoid arthritis (RA) patients on JAK inhibitors (JAKi) have an increased HZ risk compared to those on biologic DMARDs (bDMARDs). Recently, the Adjuvanted Recombinant Zoster Vaccine (RZV) became available worldwide, showing good effectiveness in patients with inflammatory arthritis. Nevertheless...

Descripción completa

Detalles Bibliográficos
Autores principales:	Venerito, Vincenzo, Stefanizzi, Pasquale, Cantarini, Luca, Lavista, Marlea, Galeone, Maria Grazia, Di Lorenzo, Antonio, Iannone, Florenzo, Tafuri, Silvio, Lopalco, Giuseppe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10138868/ https://www.ncbi.nlm.nih.gov/pubmed/37108130 http://dx.doi.org/10.3390/ijms24086967

Ejemplares similares

Immunogenicity of BNT162b2 mRNA SARS-CoV-2 vaccine in patients with psoriatic arthritis on TNF inhibitors
por: Venerito, Vincenzo, et al.
Publicado: (2022)

Radiomics to predict the mortality of patients with rheumatoid arthritis-associated interstitial lung disease: A proof-of-concept study
por: Venerito, Vincenzo, et al.
Publicado: (2023)

Evolution of Rheumatoid-Arthritis-Associated Interstitial Lung Disease in Patients Treated with JAK Inhibitors: A Retrospective Exploratory Study
por: Venerito, Vincenzo, et al.
Publicado: (2023)

COVID-19, rheumatic diseases and immunosuppressive drugs: an appeal for medication adherence
por: Venerito, Vincenzo, et al.
Publicado: (2020)

Comparison of Adalimumab to Other Targeted Therapies in Rheumatoid Arthritis: Results from Systematic Literature Review and Meta-Analysis
por: Cacciapaglia, Fabio, et al.
Publicado: (2022)

Cytokine Signatures in Mucocutaneous and Ocular Behçet’s Disease
por: Lopalco, Giuseppe, et al.
Publicado: (2017)

Fibrosing Progressive Interstitial Lung Disease in Rheumatoid Arthritis: A Multicentre Italian Study
por: Sebastiani, Marco, et al.
Publicado: (2023)

4. Immunogenicity of the Adjuvanted Recombinant Zoster Vaccine in Immunocompromised Adults
por: Dagnew, Alemnew F, et al.
Publicado: (2020)

Immunogenicity of third dose of anti-SARS-CoV-2 vaccine co-administered with influenza vaccine: An open question
por: Stefanizzi, Pasquale, et al.
Publicado: (2022)

Update on the Medical Management of Gastrointestinal Behçet's Disease
por: Lopalco, Giuseppe, et al.
Publicado: (2017)

Immunogenicity and safety of BNT162b2 mRNA COVID-19 vaccine in a subject affected by Shapiro’s syndrome: A case report
por: Moscara, Lorenza, et al.
Publicado: (2022)

A Machine Learning Approach to Predict Remission in Patients With Psoriatic Arthritis on Treatment With Secukinumab
por: Venerito, Vincenzo, et al.
Publicado: (2022)

Lipids and Atherogenic Indices Fluctuation in Rheumatoid Arthritis Patients on Long-Term Tocilizumab Treatment
por: Cacciapaglia, Fabio, et al.
Publicado: (2018)

Basic Characteristics of Adults with Periodic Fever, Aphthous Stomatitis, Pharyngitis, and Adenopathy Syndrome in Comparison with the Typical Pediatric Expression of Disease
por: Cattalini, Marco, et al.
Publicado: (2015)

Interleukin-1 as a Common Denominator from Autoinflammatory to Autoimmune Disorders: Premises, Perils, and Perspectives
por: Lopalco, Giuseppe, et al.
Publicado: (2015)

Long-term Immunogenicity of Measles Vaccine: An Italian Retrospective Cohort Study
por: Bianchi, Francesco Paolo, et al.
Publicado: (2020)

Putative Role of Serum Amyloid-A and Proinflammatory Cytokines as Biomarkers for Behcet's Disease
por: Lopalco, Giuseppe, et al.
Publicado: (2015)

Long-term immunogenicity after measles vaccine vs. wild infection: an Italian retrospective cohort study
por: Bianchi, Francesco Paolo, et al.
Publicado: (2021)

Unveiling the Efficacy, Safety, and Tolerability of Anti-Interleukin-1 Treatment in Monogenic and Multifactorial Autoinflammatory Diseases
por: Bettiol, Alessandra, et al.
Publicado: (2019)

Long-Term Immunogenicity of Inactivated and Oral Polio Vaccines: An Italian Retrospective Cohort Study
por: Larocca, Angela Maria Vittoria, et al.
Publicado: (2022)

Mucocutaneous Involvement in Behçet's Disease: How Systemic Treatment Has Changed in the Last Decades and Future Perspectives
por: Rotondo, Cinzia, et al.
Publicado: (2015)

Management of Takayasu arteritis diagnosed during pregnancy: A case report
por: AREZZO, Francesca, et al.
Publicado: (2020)

AI am a rheumatologist: a practical primer to large language models for rheumatologists
por: Venerito, Vincenzo, et al.
Publicado: (2023)

Healthy ageing: Herpes zoster infection and the role of the adjuvanted recombinant zoster vaccine
por: Curran, D, et al.
Publicado: (2022)

Sarcopenia in Patients with Rheumatic Diseases: Prevalence and Associated Risk Factors
por: Barone, Michele, et al.
Publicado: (2018)

Long-Term Effectiveness of Secukinumab in Patients with Axial Spondyloarthritis
por: Gentileschi, Stefano, et al.
Publicado: (2020)

Uncovering the Underworld of Axial Spondyloarthritis
por: Del Vescovo, Sergio, et al.
Publicado: (2023)

The public health and the question of the “best vaccine”
por: Tafuri, Silvio, et al.
Publicado: (2022)

Long-term Protection Against Herpes Zoster by the Adjuvanted Recombinant Zoster Vaccine: Interim Efficacy, Immunogenicity, and Safety Results up to 10 Years After Initial Vaccination
por: Strezova, Ana, et al.
Publicado: (2022)

From Bench to Bedside in Rheumatoid Arthritis from the “2022 GISEA International Symposium”
por: Vitale, Antonio, et al.
Publicado: (2023)

Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in patients with solid tumors, vaccinated before or during chemotherapy: A randomized trial
por: Vink, Peter, et al.
Publicado: (2019)

Immunogenicity of the Adjuvanted Recombinant Zoster Vaccine: Persistence and Anamnestic Response to Additional Doses Administered 10 Years After Primary Vaccination
por: Hastie, Andrew, et al.
Publicado: (2020)

Association Between Immunogenicity and Reactogenicity: A Post Hoc Analysis of 2 Phase 3 Studies With the Adjuvanted Recombinant Zoster Vaccine
por: Callegaro, Andrea, et al.
Publicado: (2021)

Proinflammatory Cytokines and Antiskin Autoantibodies in Patients With Inherited Epidermolysis Bullosa
por: Annicchiarico, Giuseppina, et al.
Publicado: (2015)

Adalimumab Accounts for Long-Term Control of Noninfectious Uveitis Also in the Absence of Concomitant DMARD Treatment: A Multicenter Retrospective Study
por: Bitossi, Alice, et al.
Publicado: (2019)

Post-Marketing Safety Surveillance for the Adjuvanted Recombinant Zoster Vaccine: Methodology
por: Tavares-Da-Silva, Fernanda, et al.
Publicado: (2020)

Immunogenicity and Safety of the Adjuvanted Recombinant Zoster Vaccine in Chronically Immunosuppressed Adults Following Renal Transplant: A Phase 3, Randomized Clinical Trial
por: Vink, Peter, et al.
Publicado: (2020)

Validity of Machine Learning in Predicting Giant Cell Arteritis Flare After Glucocorticoids Tapering
por: Venerito, Vincenzo, et al.
Publicado: (2022)

Immunogenicity and Safety of Beta-Adjuvanted Recombinant Booster Vaccine
por: Launay, Odile, et al.
Publicado: (2022)

An update on national recommendations for the use of the adjuvanted recombinant zoster vaccine: Romy Weller
por: Parikh, R, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_fqloni38tjs2oinjejnpelm222